REGN9933A2与REGN7508Cat预防术后静脉血栓栓塞的有效性和安全性(ROXI-VTE-I和ROXI-VTE-II):两项随机、开放标签、2期试验
ROXI-VTE-I和ROXI-VTE-II是两项随机、开放标签、2期研究,纳入≥50岁膝关节置换术患者,分别比较REGN9933A2与依诺肝素(以阿哌沙班为探索性对照)以及REGN7508Cat与依诺肝素预防静脉血栓栓塞的效果。主要终点为用药后第12天前客观确认的静脉血栓栓塞。ROXI-VTE-I中REGN9933A2组静脉血栓栓塞发生率17%,依诺肝素组22%,aOR 0.78(90%可信区间0.47-1.32),后验概率78.5%,未达优于依诺肝素的标准。ROXI-VTE-II中REGN7508Cat组发生率7%,依诺肝素组17%,aOR 0.37(0.20-0.68),后验概率99.8%,优于依诺肝素。所有组均无主要或临床相关非主要出血。
要点
- ROXI-VTE-II中,REGN7508Cat 250 mg单次静脉给药组静脉血栓栓塞发生率7%(8/113),依诺肝素40 mg皮下每日一次组17%(10/58),aOR 0.37(95%CI 0.20-0.68),后验概率99.8%达到优于标准。
- ROXI-VTE-I中,REGN9933A2 300 mg单次静脉给药组静脉血栓栓塞发生率17%(20/116),依诺肝素组22%(26/117),aOR 0.78(90%可信区间0.47-1.32),后验概率78.5%未达到优于标准。
- 两项研究中所有组均无主要或临床相关非主要出血事件。
- ROXI-VTE-I中阿哌沙班2.5 mg口服每日两次组静脉血栓栓塞发生率12%(14/113),为探索性对照。
- REGN7508Cat组最常见治疗中出现的不良事件为术后贫血(5%,6/120),REGN9933A2组为7%(9/123)。
适用人群与场景
- 两项研究均纳入年龄≥50岁、接受膝关节置换术的患者。
- ROXI-VTE-I在7个国家15个中心进行,ROXI-VTE-II在5个国家12个中心进行。
诊断标准与关键阈值
- 主要终点为首次给药后第12天前客观确认的静脉血栓栓塞,包括手术腿无症状深静脉血栓、任一侧腿客观确认的症状性深静脉血栓或确认的非致命性或致命性肺栓塞。
- 主要分析在改良意向治疗人群中进行:随机分配、至少接受一剂研究治疗、且具有可评估静脉造影或确认的症状性静脉血栓栓塞的患者。
- 若对数比值比(OR)<0的后验概率>95%,则认为REGN9933A2或REGN7508Cat优于依诺肝素。
处置流程与药物剂量
- ROXI-VTE-I:术后随机1:1:1接受REGN9933A2 300 mg静脉注射一次、依诺肝素40 mg皮下注射每日一次或阿哌沙班2.5 mg口服每日两次(探索性对照)。
- ROXI-VTE-II:术后随机2:1接受REGN7508Cat 250 mg静脉注射一次或依诺肝素40 mg皮下注射每日一次。
- 研究药物在手术结束后12-24小时给药;依诺肝素和阿哌沙班持续至静脉造影日或第12天(以较早者为准)。
研究设计与关键结果
- ROXI-VTE-I纳入373例患者(2023年5月24日至2024年5月27日),ROXI-VTE-II纳入179例患者(2024年6月27日至2025年1月21日),中位随访74天(IQR 72-76)。
- ROXI-VTE-I第12天静脉血栓栓塞发生率:REGN9933A2组17%(20/116),依诺肝素组22%(26/117),阿哌沙班组12%(14/113);REGN9933A2 vs 依诺肝素平均调整OR 0.78(90%可信区间0.47-1.32),后验概率78.5%。
- ROXI-VTE-II第12天静脉血栓栓塞发生率:REGN7508Cat组7%(8/113),依诺肝素组17%(10/58);REGN7508Cat vs 合并依诺肝素组平均调整OR 0.37(95%CI 0.20-0.68),后验概率99.8%。
- 所有组均无主要或临床相关非主要出血。
- ROXI-VTE-I中最常见治疗中出现的不良事件为术后贫血:REGN9933A2组7%(9/123),依诺肝素组9%(11/125),阿哌沙班组13%(16/125);ROXI-VTE-II中REGN7508Cat组5%(6/120)。
- 严重不良事件:ROXI-VTE-I中REGN9933A2组3%(4例)、依诺肝素组1%(1例)、阿哌沙班组2%(2例);ROXI-VTE-II中REGN7508Cat组2%(2例),依诺肝素组0例。无治疗相关死亡。
证据类型、等级与局限
- 证据类型:两项随机、开放标签、2期试验(ROXI-VTE-I和ROXI-VTE-II)。
对床旁实践的改变
- 作者认为,REGN7508Cat的结果证实了FXI在术后静脉血栓栓塞中的作用;REGN9933A2的结果提示FXIIa驱动的FXI激活参与该过程。
- REGN7508Cat在膝关节置换术后患者中预防静脉血栓栓塞优于依诺肝素,且未增加出血,但为2期试验结果。
- REGN9933A2在膝关节置换术后患者中未优于依诺肝素。
指南或共识出处
- ROXI-VTE-I和ROXI-VTE-II注册于ClinicalTrials.gov(NCT05618808和NCT06454630)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Coagulation factor XI (FXI) inhibitors can reduce the incidence of thrombosis without increasing bleeding risk. FXI is activated by factor XIIa (FXIIa) or thrombin. REGN7508Cat is an antibody that binds to the FXI catalytic domain, blocking both its activity and activation by FXIIa and thrombin. REGN9933A2 binds to the FXI apple 2 domain and blocks FXI activation by FXIIa. We aimed to compare the efficacy and safety of REGN9933A2 and enoxaparin, with apixaban as an exploratory comparator, and REGN7508Cat and enoxaparin for venous thromboembolism prevention.
METHODS: ROXI-VTE-I and ROXI-VTE-II are randomised, open-label, phase 2 studies in patients (aged ≥50 years) undergoing knee arthroplasty across 15 centres in seven countries and 12 centres in five countries, respectively. In ROXI-VTE-I, patients were randomised (1:1:1) to receive REGN9933A2 (300 mg intravenously once), enoxaparin (40 mg subcutaneously once daily), or apixaban (2·5 mg orally twice a day; an exploratory comparator) after surgery. In ROXI-VTE-II, patients were randomised (2:1) to receive REGN7508Cat (250 mg intravenously once) or enoxaparin (40 mg subcutaneously once daily) after surgery. Enoxaparin and apixaban were continued through the day of venography or day 12, whichever was earlier. The primary endpoint in both studies was objectively confirmed venous thromboembolism (a composite of asymptomatic deep-vein thrombosis of the operated leg, objectively confirmed symptomatic deep-vein thrombosis of either leg, or confirmed non-fatal or fatal pulmonary embolism) through day 12 after the first dose of study drug (administered 12-24 h after the end of surgery). In the modified intention-to-treat population (randomly allocated patients who received at least one dose of study treatment and had either an evaluable venogram or confirmed symptomatic venous thromboembolism) for the primary analyses, REGN9933A2 or REGN7508Cat was considered superior to enoxaparin if the posterior probability that the log odds ratio (OR) <0 was greater than 95%. For ROXI-VTE-II, the OR was estimated for REGN7508Cat versus the combined enoxaparin groups of ROXI-VTE-I (discounted by half) and ROXI-VTE-II. The main safety outcome was the composite of major and clinically relevant non-major bleeding. ROXI-VTE-I and ROXI-VTE-II are registered with ClinicalTrials.gov (NCT05618808 and NCT06454630).
FINDINGS: Patients were enrolled from May 24, 2023, to May 27, 2024, in ROXI-VTE-I (n=373) and from June 27, 2024, to Jan 21, 2025, in ROXI-VTE-II (n=179). The median follow-up time was 74 days (IQR 72-76) for both studies. In ROXI-VTE-I, venous thromboembolism occurred in 20 (17%) of 116 patients in the REGN9933A2 group, 26 (22%) of 117 in the enoxaparin group, and 14 (12%) of 113 in the apixaban group through day 12. For REGN9933A2 versus enoxaparin, the mean adjusted OR (aOR) was 0·78 (90% credible interval 0·47-1·32); the posterior probability was 78·5%. In ROXI-VTE-II, venous thromboembolism occurred in eight (7%) of 113 in the REGN7508Cat group and ten (17%) of 58 patients in the enoxaparin group through day 12. For REGN7508Cat versus the combined enoxaparin groups, the mean aOR was 0·37 (0·20-0·68); the posterior probability was 99·8%. There were no major or clinically relevant non-major bleeds in any group. The most common treatment-emergent adverse event was postoperative anaemia (nine [7%] of 123 patients in the REGN9933A2 group, 11 [9%] of 125 in the enoxaparin group, and 16 [13%] of 125 in the apixaban group in ROXI-VTE-I; and six [5%] of 120 in the REGN7508Cat group in ROXI-VTE-II). Serious adverse events occurred in four (3%), one (1%), and two (2%) patients given REGN9933A2, enoxaparin, and apixaban in ROXI-VTE-I; and in two (2%) patients who received REGN7508Cat and none who received enoxaparin in ROXI-VTE-II. No treatment-related deaths occurred.
INTERPRETATION: REGN7508Cat was superior to enoxaparin for venous thromboembolism prevention; REGN9933A2 was not superior to enoxaparin. The findings with REGN7508Cat confirm the role of FXI in postoperative venous thromboembolism, and the findings with REGN9933A2 suggest that FXIIa-driven FXI activation contributes to this process.
FUNDING: Regeneron Pharmaceuticals.
参考来源
- Weitz JI, Kithcart AP, O'Brien MP, et al. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025. PMID: 41218619. doi:10.1016/S0140-6736(25)02097-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。